Trial Profile
Randomised, Open Label, 3-way Cross Over Phase I Study to Investigate the Impact of Concomitant Use of Multiple Doses of Clopidogrel (75 mg qd After a Loading Dose of 300 mg) With Multiple Doses of Dabigatran Etexilate (150 mg Bid) on the Pharmacokinetic and Pharmacodynamic Parameters, and Additionally the Impact of Single Oral Doses of 300 mg and 600 mg of Clopidogrel Administered Under Steady State Conditions of Dabigatran of 75 mg and 150 mg in Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Clopidogrel
- Indications Arterial occlusive disorders; Cardiovascular disorders; Deep vein thrombosis; Ischaemic heart disorders; Myocardial ischaemia; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 28 Jun 2014 New trial record